**b**|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

Monoclonal Antibody SAI131-5D5 Anti-*Plasmodium falciparum* Circumsporozoite Protein (rCSP), Full-Length Recombinant

Catalog No. MRA-1242

For research use only. Not for human use.

#### **Contributor and Manufacturer:**

Gabriel M. Gutierrez, Ph.D., Program Manager, Leidos Inc., Frederick, Maryland, USA

## **Product Description:**

Antibody Class: IgG (subclass unknown)

Mouse monoclonal antibody prepared against two overlapping peptides on the N-terminus of full-length *Plasmodium falciparum* recombinant circumsporozoite protein (rCSP). The SAI131-5D5 monoclonal antibody recognizes CSP in live sporozoites, inhibits CSP processing, and inhibits infection of hepatocytes in a mouse model.<sup>1,2</sup>

#### **Material Provided:**

Each vial of MRA-1242 contains approximately 40  $\mu$ L of purified monoclonal antibody SAI131-5D5 in PBS (concentration: 1 mg per mL).

## Packaging/Storage:

MRA-1242 was packaged aseptically in screw-capped plastic cryovials and is provided frozen on dry ice. The product should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

#### **Functional Activity:**

Monoclonal antibody SAI131-5D5 is reported to function in ELISA, Western blot, immunofluorescence assays, and vaccine studies.<sup>1-3</sup>

#### Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Antibody SAI131-5D5 Anti-*Plasmodium falciparum* Circumsporozoite Protein (rCSP), Full-Length Recombinant, MRA-1242, contributed by Gabriel M. Gutierrez."

#### **Biosafety Level: 1**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in</u> <u>Microbiological and Biomedical Laboratories</u>. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

# Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at <u>www.beiresources.org</u>.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC<sup>®</sup> nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC<sup>®</sup> nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC<sup>®</sup> and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC<sup>®</sup>, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

#### **Use Restrictions:**

This material is distributed for internal research, noncommercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

#### **References:**

- Noe, A. R., et al. "A Full-Length *Plasmodium falciparum* Recombinant Circumsporozoite Protein Expressed by *Pseudomonas fluorescens* Platform as a Malaria Vaccine Candidate." <u>PLoS One</u> 9 (2014): e107764. PubMed: 25247295.
- Espinosa, D. A., et al. "Proteolytic Cleavage of the *Plasmodium falciparum* Circumsporozoite Protein Is a Target of Protective Antibodies." <u>J. Infect. Dis.</u> 212 (2015): 1111-1119. PubMed: 25762791.
- 3. Gutierrez., G. M., Personal Communication.

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection.



E-mail: contact@beiresources.org Tel: 800-359-7370 Fax: 703-365-2898